Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2326-2328
10.1182/blood-2022-160386